Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer

Inclusion Criteria:

* Age 65 years and above;
* Histologically or cytologically documented adenocarcinoma of the colon or rectum;
* Metastatic disease;
* Measurable disease or assessable but nonmeasurable disease allowed;
* ECOG 0-1
* No prior oxaliplatin or bevacizumab.
* No prior chemotherapy for metastatic disease. Prior adjuvant chemotherapy allowed;
* No prior fluoropyrimidine therapy (unless give in an adjuvant setting and completed at least 4 months earlier);
* No bleeding diathesis or coagulopathy
* Adequate renal and hepatic functions as per protocol;
* Signed informed consent

Exclusion Criteria:

* Clinically significant cardiovascular or peripheral vascular disease;
* Concurrent chronic aspirin, nonsteroidal anti-inflammatory drugs, warfarin, or therapeutic heparin;
* Serious non-healing wound, ulcer, or bone fracture;